Stryker (NYSE:SYK) issued an update on its FY17 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $6.45-6.50 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.48. The company issued revenue guidance of $12.4 billion, compared to the consensus revenue estimate of $12.37 billion.
Shares of Stryker (NYSE SYK) traded up $2.20 on Tuesday, reaching $163.26. 1,240,200 shares of the company traded hands, compared to its average volume of 1,104,940. The company has a quick ratio of 1.61, a current ratio of 2.37 and a debt-to-equity ratio of 0.63. The company has a market cap of $60,100.00, a P/E ratio of 34.81, a PEG ratio of 2.30 and a beta of 0.78. Stryker has a 12-month low of $117.64 and a 12-month high of $163.74.
Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, October 26th. The medical technology company reported $1.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.50 by $0.02. The company had revenue of $3.01 billion for the quarter, compared to analyst estimates of $2.97 billion. Stryker had a net margin of 14.67% and a return on equity of 24.11%. The business’s quarterly revenue was up 6.1% on a year-over-year basis. During the same period last year, the business posted $1.39 EPS. equities research analysts forecast that Stryker will post 6.47 EPS for the current year.
Several analysts have recently weighed in on SYK shares. Wells Fargo & Co lifted their target price on shares of Stryker from $160.00 to $166.00 in a research report on Friday, October 27th. Canaccord Genuity lifted their target price on shares of Stryker from $155.00 to $162.00 and gave the company a buy rating in a research report on Friday, October 27th. Stifel Nicolaus lifted their target price on shares of Stryker from $158.00 to $168.00 and gave the company a buy rating in a research report on Friday, October 27th. Cowen set a $160.00 target price on shares of Stryker and gave the company a buy rating in a research report on Friday, October 6th. Finally, Royal Bank of Canada reiterated a buy rating and set a $155.00 target price on shares of Stryker in a research report on Monday, October 2nd. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and thirteen have given a buy rating to the company. The stock has an average rating of Hold and an average price target of $155.10.
In other Stryker news, insider Lonny J. Carpenter sold 5,000 shares of the business’s stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $155.34, for a total value of $776,700.00. Following the completion of the transaction, the insider now directly owns 83,207 shares of the company’s stock, valued at $12,925,375.38. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 7.40% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.com-unik.info/2018/01/09/stryker-syk-updates-fy17-earnings-guidance.html.
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.